MRNA - Moderna, Inc.
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Thursday.
The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement.
Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.
Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.
Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.
The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands at about $55.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.
Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the overall public health risk remains low. The stock rose 9.43% to $59.48, its intraday high after a US national tested mildly positive for the Andes strain of hantavirus.
Top insights from the latest market news from Monday, May 11, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.
Moderna Inc (NASDAQ:MRNA) shares are trading higher during Monday's pre-market session as investors focus shifts to an emerging global health concern, a hantavirus outbreak, that has highlighted the company's specialized research pipeline. Here's what investors need to know.
Stock futures are quietly lower this morning after President Donald Trump rejected Iran's proposal
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.